390 related articles for article (PubMed ID: 33547233)
1. Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling.
Zhang H; You X; Wang X; Cui L; Wang Z; Xu F; Li M; Yang Z; Liu J; Huang P; Kang Y; Wu J; Xia X
Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33547233
[TBL] [Abstract][Full Text] [Related]
2. RNA cancer vaccines: developing mRNA nanovaccine with self-adjuvant property for cancer immunotherapy.
Zhang H; Xia X
Hum Vaccin Immunother; 2021 Sep; 17(9):2995-2998. PubMed ID: 33945399
[TBL] [Abstract][Full Text] [Related]
3. Tumor Lysate-Loaded Lipid Hybrid Nanovaccine Collaborated with an Immune Checkpoint Antagonist for Combination Immunotherapy.
Hu X; Wu T; Qin X; Qi Y; Qiao Q; Yang C; Zhang Z
Adv Healthc Mater; 2019 Jan; 8(1):e1800837. PubMed ID: 30506847
[TBL] [Abstract][Full Text] [Related]
4. Mild Innate Immune Activation Overrides Efficient Nanoparticle-Mediated RNA Delivery.
Lokugamage MP; Gan Z; Zurla C; Levin J; Islam FZ; Kalathoor S; Sato M; Sago CD; Santangelo PJ; Dahlman JE
Adv Mater; 2020 Jan; 32(1):e1904905. PubMed ID: 31743531
[TBL] [Abstract][Full Text] [Related]
5. mRNA-transfected Dendritic Cells Expressing Polypeptides That Link MHC-I Presentation to Constitutive TLR4 Activation Confer Tumor Immunity.
Cafri G; Sharbi-Yunger A; Tzehoval E; Alteber Z; Gross T; Vadai E; Margalit A; Gross G; Eisenbach L
Mol Ther; 2015 Aug; 23(8):1391-1400. PubMed ID: 25997427
[TBL] [Abstract][Full Text] [Related]
6. Development of a lipoplex-type mRNA carrier composed of an ionizable lipid with a vitamin E scaffold and the KALA peptide for use as an ex vivo dendritic cell-based cancer vaccine.
Tateshita N; Miura N; Tanaka H; Masuda T; Ohtsuki S; Tange K; Nakai Y; Yoshioka H; Akita H
J Control Release; 2019 Sep; 310():36-46. PubMed ID: 31386869
[TBL] [Abstract][Full Text] [Related]
7. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
[TBL] [Abstract][Full Text] [Related]
8. Supramolecular Lipid Nanoparticles Based on Host-Guest Recognition: A New Generation Delivery System of mRNA Vaccines For Cancer Immunotherapy.
Qi S; Zhang X; Yu X; Jin L; Yang K; Wang Y; Feng Y; Lei J; Mao Z; Yu G
Adv Mater; 2024 Jun; 36(23):e2311574. PubMed ID: 38433564
[TBL] [Abstract][Full Text] [Related]
9. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy.
Oberli MA; Reichmuth AM; Dorkin JR; Mitchell MJ; Fenton OS; Jaklenec A; Anderson DG; Langer R; Blankschtein D
Nano Lett; 2017 Mar; 17(3):1326-1335. PubMed ID: 28273716
[TBL] [Abstract][Full Text] [Related]
10. Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity.
Chiang CY; Chen YJ; Wu CC; Liu SJ; Leng CH; Chen HW
Front Immunol; 2018; 9():822. PubMed ID: 29755461
[TBL] [Abstract][Full Text] [Related]
11. Probiotic-derived amphiphilic exopolysaccharide self-assembling adjuvant delivery platform for enhancing immune responses.
Sheng S; Zhang H; Li X; Chen J; Wang P; Liang Y; Li C; Li H; Pan N; Bao X; Liu M; Zhao L; Li X; Guan P; Wang X
J Nanobiotechnology; 2024 May; 22(1):267. PubMed ID: 38764014
[TBL] [Abstract][Full Text] [Related]
12. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.
Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z
J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522
[TBL] [Abstract][Full Text] [Related]
13. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
[TBL] [Abstract][Full Text] [Related]
14. α-Galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma.
Sainz V; Moura LIF; Peres C; Matos AI; Viana AS; Wagner AM; Vela Ramirez JE; S Barata T; Gaspar M; Brocchini S; Zloh M; Peppas NA; Satchi-Fainaro R; F Florindo H
Acta Biomater; 2018 Aug; 76():193-207. PubMed ID: 29940370
[TBL] [Abstract][Full Text] [Related]
15. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy.
Song H; Su Q; Shi W; Huang P; Zhang C; Zhang C; Liu Q; Wang W
Acta Biomater; 2022 Mar; 141():398-407. PubMed ID: 35007785
[TBL] [Abstract][Full Text] [Related]
16. Funiculosin variants and phosphorylated derivatives promote innate immune responses via the Toll-like receptor 4/myeloid differentiation factor-2 complex.
Okamoto N; Mizote K; Honda H; Saeki A; Watanabe Y; Yamaguchi-Miyamoto T; Fukui R; Tanimura N; Motoi Y; Akashi-Takamura S; Kato T; Fujishita S; Kimura T; Ohto U; Shimizu T; Hirokawa T; Miyake K; Fukase K; Fujimoto Y; Nagai Y; Takatsu K
J Biol Chem; 2017 Sep; 292(37):15378-15394. PubMed ID: 28754693
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of Tumor RNA-Loaded Lipid Nanoparticles Against Hepatocellular Carcinoma.
Zhang Y; Xie F; Yin Y; Zhang Q; Jin H; Wu Y; Pang L; Li J; Gao J
Int J Nanomedicine; 2021; 16():1553-1564. PubMed ID: 33658783
[TBL] [Abstract][Full Text] [Related]
18. Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity.
Wang Z; Xu F; Hu J; Zhang H; Cui L; Lu W; He W; Wang X; Li M; Zhang H; Xiong W; Xie C; Liu Y; Zhou P; Liu J; Huang P; Qin XF; Xia X
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016722
[TBL] [Abstract][Full Text] [Related]
19. Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma.
Guo Y; Wang D; Song Q; Wu T; Zhuang X; Bao Y; Kong M; Qi Y; Tan S; Zhang Z
ACS Nano; 2015 Jul; 9(7):6918-33. PubMed ID: 26153897
[TBL] [Abstract][Full Text] [Related]
20. A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccine.
Park HJ; Jang GY; Kim YS; Park JH; Lee SE; Vo MC; Lee JJ; Han HD; Jung ID; Kang TH; Park YM
J Immunother Cancer; 2019 Feb; 7(1):60. PubMed ID: 30819254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
